PPARD and early-onset autosomal dominant Alzheimer disease: Similar to AICAR and metformin, GW501516 and GW0742 increased memory performance and enhanced hippocampal neurogenesis as well.370,384 Thus, a phase IIa clinical study was carried out to test T3D-959, a newly synthetic PPARδ agonist, in subjects with mild to moderate Alzheimer’s disease, which suggests that PPARδ agonists are also moving towards clinical translation.385